He said the committee's investigation would focus on key areas, such as the rising misuse of codeine-laced syrups, tramadol, and other controlled drugs; the illegal production and distribution of cheap spirits and counterfeit alcoholic beverages; and the unethical targeting of minors in alcohol and tobacco advertising. According to him, the panel will also examine the circulation of fake, unregistered, and substandard pharmaceutical products, weak regulatory frameworks, and instances of corporate complicity that compromise public health. He stressed that the committee's priority is to safeguard lives and uphold national interest over corporate profits, insisting that an era of impunity and lax regulation must end.